Drug Profile
ReN 001
Alternative Names: CTX 0E03; ReN-001Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator ReNeuron
- Class Neural stem cell therapies; Neuroprotectants
- Mechanism of Action Cell replacements; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Stroke
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for phase-I development in Stroke(In the elderly) in Scotland (Intracerebral, Implant)
- 14 Jul 2021 ReNeuron terminates the phase IIb PISCES III trial in Ischemic stroke in USA (Intracerebral), due to strategic decision to progress stroke disability programme through regional partnerships (NCT03629275)
- 17 Jun 2020 Fosun Pharma files CTA in China for phase IIb trial in Stroke